Native Kidney Denervation in Patients With End Stage Renal Disease
NCT ID: NCT00551304
Last Updated: 2012-11-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
INTERVENTIONAL
2007-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ardian Catheter
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* end stage renal disease, undergoing concurrent dialysis treatment
* poorly controlled blood pressure on at least 2 antihypertensive drugs
* agrees to have the study procedure(s) performed and additional procedures and evaluations, including interventions and follow up visits
* competent and willing to provide written, informed consent to participate in this clinical study.
Exclusion Criteria
* myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within six (6) months
* hemodynamically significant valvular heart disease
* implantable cardioverter defibrillator (ICD) or pacemaker
* respiratory support.
* pregnant, nursing or planning to be pregnant
* other
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medtronic Vascular
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Markus Schlaich, MD
Role: PRINCIPAL_INVESTIGATOR
The Alfred
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Alfred Hospital
Melbourne, Victoria, Australia
John Paull II Hosptial
Krakow, , Poland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Schlaich MP, Hering D, Sobotka PA, Krum H, Esler MD. Renal denervation in human hypertension: mechanisms, current findings, and future prospects. Curr Hypertens Rep. 2012 Jun;14(3):247-53. doi: 10.1007/s11906-012-0264-9.
Hering D, Esler MD, Krum H, Mahfoud F, Bohm M, Sobotka PA, Schlaich MP. Recent advances in the treatment of hypertension. Expert Rev Cardiovasc Ther. 2011 Jun;9(6):729-44. doi: 10.1586/erc.11.71.
Schlaich MP, Sobotka PA, Krum H, Whitbourn R, Walton A, Esler MD. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension. 2009 Dec;54(6):1195-201. doi: 10.1161/HYPERTENSIONAHA.109.138610. Epub 2009 Oct 12. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TP-020 & TP-039
Identifier Type: -
Identifier Source: org_study_id